|
Apr 24
|
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
|
|
Apr 24
|
BioMarin Reports Record Financial Results for the First Quarter 2024
|
|
Apr 23
|
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
|
|
Apr 23
|
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
|
|
Apr 22
|
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says
|
|
Apr 22
|
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
|
|
Apr 18
|
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
|
|
Apr 17
|
BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Apr 12
|
Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...
|
|
Apr 10
|
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
|
|
Apr 1
|
Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ...
|
|
Mar 28
|
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
|
|
Mar 16
|
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
|
|
Mar 12
|
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
|
|
Mar 11
|
BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth
|
|
Mar 8
|
Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ...
|
|
Mar 7
|
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
|
|
Feb 27
|
Decoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT Insight
|
|
Feb 26
|
REFILE-UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies
|
|
Feb 24
|
BioMarin Pharmaceutical Full Year 2023 Earnings: EPS: US$0.89 (vs US$0.76 in FY 2022)
|